Skip to main content
. 2019 Jun 10;26(1):103–111. doi: 10.1093/ibd/izz113

FIGURE 4.

FIGURE 4.

A, Proportion of patients currently on IFX experiencing a flare at each time step; (b) proportion of patients in the cohort who never experienced a flare; (c) Mean IFX concentration at each time step; (d) Proportion of patients who develop anti-IFX antibodies over time. Bands around lines represent the standard errors of the means.